Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

References

• SwerdlowSHCampoEHarrisNLWorld Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues4th EditionLyon FranceIARC Press2008
   Google Scholar
• MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMSLymphoma incidence patterns by WHO subtype in the United States, 1992–2001Blood2006107126527616150940
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma Classification ProjectBlood19978911390939189166827
   PubMed Web of Science ®Google Scholar
• MaloneyDGSmithBRoseARituximab: mechanism of action and resistanceSemin Oncol2002291 Suppl 22911842383
   PubMed Web of Science ®Google Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• PettengellRLinchDPosition paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin’s lymphomaBr J Haematol20031211444812670330
   PubMed Web of Science ®Google Scholar
• SehnLHDonaldsonJChhanabhaiMIntroduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaJ Clin Oncol200523225027503315955905
   PubMed Web of Science ®Google Scholar
• PfreundschuhMTrumperLOsterborgACHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupLancet Oncol20067537939116648042
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• FeugierPVan HoofASebbanCLong-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’AdulteJ Clin Oncol200523184117412615867204
   PubMed Web of Science ®Google Scholar
• HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935
   PubMed Web of Science ®Google Scholar
• PfreundschuhMSchubertJZiepertMSix versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Lancet Oncol20089210511618226581
   PubMed Web of Science ®Google Scholar
• CoiffierBFeugierPMounierLong-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patientsJ Clin Oncol (Meeting Abstracts)20072518 suppl8009
   Google Scholar
• MorrisonVAWellerEAHabermannMaintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 updateJ Clin Oncol (Meeting Abstracts)20072518_suppl8011
   Web of Science ®Google Scholar
• KewalramaniTZelenetzADNimerSDRituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaBlood2004103103684368814739217
   PubMed Web of Science ®Google Scholar
• HertzbergMCrombieCBensonWOutpatient fractionated ifosfamide, carboplatin, and etoposide as salvage therapy in relapsed and refractory non-Hodgkin’s and hodgkin’s lymphomaAnn Oncol200617iv2516702181
   PubMed Web of Science ®Google Scholar
• GrebABohliusJSchieferDSchwarzerGSchulzHEngertAHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adultsCochrane Database Syst Rev20081CD00402418254036
   PubMed Web of Science ®Google Scholar
• GisselbrechtCSchmitzNMounierNR-ICE versus R-DHAP in relapsed patietns with CD20 diffuse large B-cell lymphoma followed by stem cell transplantation and maintenance treatment with rituximab or not: First interim analysis of 200 patientsBlood200711011517
   Web of Science ®Google Scholar
• GisselbrechtCGlassBR-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL studyJ Clin Oncol20092715S8509
   Google Scholar
• HorwitzSMNegrinRSBlumeKGRituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaBlood2004103377778312907446
   PubMed Web of Science ®Google Scholar
• KhouriIFSalibaRMHosingCConcurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomasJ Clin Oncol200523102240224715800314
   PubMed Web of Science ®Google Scholar
• FriedbergJWTaylorMDCerhanJRFollicular lymphoma in the United States: first report of the national LymphoCare studyJ Clin Oncol20092781202120819204203
   PubMed Web of Science ®Google Scholar
• CzuczmanMSGrillo-LopezAJWhiteCATreatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapyJ Clin Oncol199917126827610458242
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood2006108103295330116873669
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKSolal-CelignyPPhase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaJ Clin Oncol200826284579458618662969
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112
   PubMed Web of Science ®Google Scholar
• RummelMJvon GruenhagenUNiederleNBendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL)Blood (ASH Annual Meeting Abstracts)2008112112596
   Web of Science ®Google Scholar
• RobinsonKSWilliamsMEvan der JagtRHPhase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphomaJ Clin Oncol200826274473447918626004
   PubMed Web of Science ®Google Scholar
• KaminskiMSTuckMEstesJ131I-tositumomab therapy as initial treatment for follicular lymphomaN Engl J Med2005352544144915689582
   PubMed Web of Science ®Google Scholar
• MorschhauserFRadfordJVan HoofAPhase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaJ Clin Oncol200826325156516418854568
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBurrisHA3rdRituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphomaJ Clin Oncol200220204261426712377971
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySMorrisseyLYardleyDAGrecoFARituximab as frontline and maintenance therapy for indolent non-Hodgkin’s lymphoma (NHL): longterm Follow-up of a Minnie Pearl Cancer Research Network Phase II trialBlood20031021a2a
   Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSBProlonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 scheduleBlood2004103124416442314976046
   PubMed Web of Science ®Google Scholar
• GhielminiMHsu SmitzSAleLong-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98J Clin Oncol20092715S8512
   Google Scholar
• VidalLGafter-GviliALeiboviciLShpilbergORituximab as maintenance therapy for patients with follicular lymphomaCochrane Database Syst Rev20092CD00655219370640
   PubMed Web of Science ®Google Scholar
• HochsterHWellerEGascoyneRDMaintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyJ Clin Oncol200927101607161419255334
   PubMed Web of Science ®Google Scholar
• NeumannFHarmsenSMartinSRituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphomaAnn Hematol2006885853053416639571
   PubMed Web of Science ®Google Scholar
• HicksLKWoodsABucksteinRRituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphomaBone Marrow Transplant200943970170819029963
   PubMed Web of Science ®Google Scholar
• van AgthovenMSonneveldPVerdonckLFUyl-de GrootCACost determinants in aggressive non-Hodgkin’s lymphomaHaematologica200590566167115921381
   PubMed Web of Science ®Google Scholar
• LeeRCZouDDemetrickDJDifrancescoLMFassbenderKStewartDCosts associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care centerValue Health200811222123018380634
   PubMed Web of Science ®Google Scholar
• HornbergerJCBestJHCost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaCancer200510381644165115756658
   PubMed Web of Science ®Google Scholar
• van AgthovenMVellengaEFibbeWEKingmaTUyl-de GrootCACost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin’s lymphoma or Hodgkin’s disease. a prospective randomised trialEur J Cancer200137141781178911549432
   PubMed Web of Science ®Google Scholar
• BredesonCMalcolmJDavisMBence-BrucklerIKearnsBHuebschLCost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC)Bone Marrow Transplant199720108898969404932
   PubMed Web of Science ®Google Scholar
• HornbergerJReyesCLubeckDValenteNEconomic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphomaLeuk Lymphoma200849222723618231908
   PubMed Web of Science ®Google Scholar
• CheungMCImrieKRFriedlichJBucksteinRLathiaNMittmannNThe impact of follicular (FL) and other indolent non-Hodgkin’s lymphomas (NHL) on work productivity-a preliminary analysisPsychooncology200918555455918942670
   PubMed Web of Science ®Google Scholar
• ShortPFVaseyJJTunceliKEmployment pathways in a large cohort of adult cancer survivorsCancer200531510361292130115700265
   PubMed Web of Science ®Google Scholar
• BestJHHornbergerJProctorSJOmnesLFJostFCost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphomaValue Health20058446247016091023
   PubMed Web of Science ®Google Scholar
• GrootMTLugtenburgPJHornbergerJHuijgensPCUyl-de GrootCACost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The NetherlandsEur J Haematol200574319420215693788
   PubMed Web of Science ®Google Scholar
• FerraraFRavasioRCost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphomaClin Drug Investig20082815565
   PubMed Web of Science ®Google Scholar
• HayslipJWSimpsonKNCost-effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remissionClin Lymphoma Myeloma200868316617018650180
   PubMedGoogle Scholar
• KastengFErlansonMHagbergHKimbyERelanderTLundkvistJCost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in SwedenActa Oncol20084761029103618607857
   PubMed Web of Science ®Google Scholar
• Witzens-HarigMReizMHeissCQuality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trialAnn Hematol2009881515718665360
   PubMed Web of Science ®Google Scholar